Uwe Richter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Uwe Richter has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dmytro V. Gospodaryov
Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, 57 Shevchenko Str., Ivano-Frankivsk, 76018, Ukraine
1 shared publication - John William Oman Ballard
School of Biosciences, University of Melbourne , Royal Parade, Parkville, Victoria 3052
1 shared publication - M. Florencia Camus
Department of Genetics, Evolution and Environment, University College London, UK
1 shared publication - Michael R. Garvin
Oregon Research Institute (ORI) Springfield Oregon USA
1 shared publication - Rob DeSalle
American Museum of Natural History New York New York USA
1 shared publication Robert McFarland
Wellcome Centre for Mitochondrial Research The Medical School Newcastle University UK
1 shared publication
Latest Publications
- Open Access
- 23 June 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1230032
Editorial: Energy-producing organelles and the nucleus: a phenomenal genomic friendship
Editorial: Energy-producing organelles and the nucleus: a phenomenal genomic friendship
- 23 June 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1230032
Open AccessEditorial: Energy-producing organelles and the nucleus: a phenomenal genomic friendship
Editorial: Energy-producing organelles and the nucleus: a phenomenal genomic friendship
- Open Access
- 29 January 2021
- Published by Wiley in FEBS Letters
- Vol. 595 (8) , 1003-1024
The molecular pathology of pathogenic mitochondrial tRNA variants
Mitochondrial diseases are clinically and genetically heterogeneous disorders, caused by pathogenic variants in either the nuclear or mitochondrial genome. This heterogeneity is particularly striking for disease caused by variants in mitochondrial DNA‐encoded tRNA (mt‐tRNA) genes, posing challenges for both the treatment of patients and understanding the molecular pathology. In this review, we consider disease caused by the two most common pathogenic mt‐tRNA variants: m.3243A>G (within MT‐TL1, encoding mt‐tRNALeu(UUR)) and m.8344A>G (within MT‐TK, encoding mt‐tRNALys), which together account for the vast majority of all mt‐tRNA‐related disease. We compare and contrast the clinical disease they are associated with, as well as their molecular pathologies, and consider what is known about the likely molecular mechanisms of disease. Finally, we discuss the role of mitochondrial–nuclear crosstalk in the manifestation of mt‐tRNA‐associated disease and how research in this area not only has the potential to uncover molecular mechanisms responsible for the vast clinical heterogeneity associated with these variants but also pave the way to develop treatment options for these devastating diseases.
- 29 January 2021
- Published by Wiley in FEBS Letters
- Vol. 595 (8) , 1003-1024
Open AccessThe molecular pathology of pathogenic mitochondrial tRNA variants
Mitochondrial diseases are clinically and genetically heterogeneous disorders, caused by pathogenic variants in either the nuclear or mitochondrial genome. This heterogeneity is particularly striking for disease caused by variants in mitochondrial DNA‐encoded tRNA (mt‐tRNA) genes, posing challenges for both the treatment of patients and understanding the molecular pathology. In this review, we consider disease caused by the two most common pathogenic mt‐tRNA variants: m.3243A>G (within MT‐TL1, encoding mt‐tRNALeu(UUR)) and m.8344A>G (within MT‐TK, encoding mt‐tRNALys), which together account for the vast majority of all mt‐tRNA‐related disease. We compare and contrast the clinical disease they are associated with, as well as their molecular pathologies, and consider what is known about the likely molecular mechanisms of disease. Finally, we discuss the role of mitochondrial–nuclear crosstalk in the manifestation of mt‐tRNA‐associated disease and how research in this area not only has the potential to uncover molecular mechanisms responsible for the vast clinical heterogeneity associated with these variants but also pave the way to develop treatment options for these devastating diseases.